Physician profile
Jagadish Bilgi
NPI 1891803102
$952.87
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $237 · 2021: $249 · 2022: $232.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $145.70 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $130.35 | 2019-2022 | |
| Tris Pharma INC | $109.21 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $108.11 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.07 | 2021-2022 | |
| Adlon Therapeutics L.P. | $83.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $71.95 | 2019-2021 | |
| Shire North American Group INC | $51.12 | 2019 | |
| Neos Therapeutics, LP | $37.15 | 2020-2021 | |
| Corium, LLC | $35.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.03 | 2020 | |
| Vertical Pharmaceuticals, LLC | $25.89 | 2019 | |
| Pfizer INC. | $14.50 | 2022 | |
| Sanofi Pasteur INC. | $14.41 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagadish Bilgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.